Boston Scientific Acquires BTG plc

Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific

December 1, 2020

Pharmaceuticals

Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.

Boston Scientific Acquires Baylis Medical Company Inc.

October 6, 2021

Medical Devices

Boston Scientific Corporation agreed to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The acquisition expands Boston Scientific’s electrophysiology and structural heart portfolios by adding Baylis’s RF NRG and VersaCross transseptal platforms and complementary guidewires, sheaths and dilators; Baylis was expected to generate nearly $200 million in net sales in 2022.

Boston Scientific Acquires Lumenis Surgical Business from Baring Private Equity Asia for $1.07B

March 3, 2021

Medical Devices

Boston Scientific has agreed to acquire the Lumenis Surgical Business from Baring Private Equity Asia/Lumenis for USD 1.07 billion, subject to closing adjustments. The deal transfers Lumenis' surgical laser portfolio and global surgical team (including its Israeli laser center of excellence) to Boston Scientific to bolster its Urology strategy, while Lumenis — still owned by BPEA — will focus on Aesthetics and Vision.

Valtech Acquires The Berndt Group (TBG)

April 7, 2022

Healthcare Services

Valtech, a global business transformation agency, has acquired The Berndt Group (TBG), a Baltimore-based digital customer experience agency focused on digital health transformations. TBG’s team of more than 80 practitioners and health-system clients (including Johns Hopkins and Penn Medicine) will bolster Valtech’s healthcare and digital experience capabilities.

Pfizer Acquires Global Blood Therapeutics for $5.4 Billion

August 8, 2022

Biotechnology

Pfizer Inc. has agreed to acquire Global Blood Therapeutics, Inc. for $68.50 per share in cash, valuing the transaction at approximately $5.4 billion including debt. The acquisition brings GBT's sickle cell disease portfolio (including Oxbryta) and pipeline to Pfizer to expand its rare hematology capabilities and accelerate access to therapies for underserved SCD patient communities.

Isovera Acquires The Boston Group

November 1, 2023

Marketing & Advertising

Isovera, a full-service digital creative agency, has acquired The Boston Group (TBG), a global marketing communications firm, to combine capabilities and expand service offerings for B2B and B2G clients. The deal will double Isovera's size and broaden its expertise across sectors including aerospace & defense, government, healthcare, financial services and utilities to deliver integrated digital and brand communications services.